Table 1.
Description of cohort outcomes and demographics
| UCLA CRRT | Cedars Sinai CRRT | UCLA Control | ||||||
|---|---|---|---|---|---|---|---|---|
| Overall | Do not recommend | Recommend | Overall | Do not recommend | Recommend | Do not recommend | ||
| n | 4161 | 1920 | 2241 | 3263 | 1462 | 1801 | 1562 | |
| Outcome, n (%) | ||||||||
| Comfort Care | 1179 (28.3) | 1179 (61.4) | - | 984 (30.2) | 984 (67.3) | - | - | |
| Expired | 741 (17.8) | 741 (38.6) | - | 478 (14.6) | 478 (32.7) | - | 242 (15.5) | |
| Recovered renal function | 602 (14.5) | - | 602 (26.9) | 704 (21.6) | - | 704 (39.1) | - | |
| Transitioned to hemodialysis | 1639 (39.4) | - | 1639 (73.1) | 1097 (33.6) | - | 1097 (60.9) | - | |
| Total days on CRRT, median [Q1, Q3] | 6.0 [3.0,12.0] | 5.0 [2.0,12.0] | 6.0 [3.0,12.0] | 5.0 [3.0,10.0] | 4.0 [2.0,9.0] | 6.0 [4.0,11.0] | 0.0 [0.0,0.0] | |
| Year of CRRT, median [min, max] | 2018 [2015,2021] | 2018 [2015,2021] | 2018 [2015,2021] | 2019 [2016,2021] | 2019 [2016,2021] | 2019 [2016,2021] | 2019 [2016,2021] | |
| Number of previous CRRT Treatments, mean (SD) | 0.2 (0.7) | 0.1 (0.5) | 0.3 (0.8) | 0.2 (0.5) | 0.1 (0.4) | 0.2 (0.5) | 0.0 (0.0) | |
| Age, median [Q1, Q3] | 60.0 [47.0,69.0] | 60.0 [48.0,69.0] | 59.0 [45.0,68.0] | 66.0 [56.0,75.0] | 68.0 [58.0,78.0] | 63.0 [53.0,73.0] | 61.0 [48.0,70.0] | |
| Sex, n (%) | ||||||||
| Female | 1682 (40.4) | 765 (39.8) | 917 (40.9) | 1111 (36.3) | 537 (37.8) | 574 (35.0) | 627 (40.1) | |
| Male | 2479 (59.6) | 1155 (60.2) | 1324 (59.1) | 1946 (63.7) | 882 (62.2) | 1064 (65.0) | 935 (59.9) | |
| Ethnicity, n (%) | ||||||||
| Hispanic or Latino | 1416 (34.0) | 580 (30.2) | 836 (37.3) | 756 (24.7) | 307 (21.6) | 449 (27.4) | 548 (35.1) | |
| Not Hispanic or Latino | 2745 (66.0) | 1340 (69.8) | 1405 (62.7) | 2301 (75.3) | 1112 (78.4) | 1189 (72.6) | 1014 (64.9) | |
| Race, n (%) | ||||||||
| American Indian or Alaska Native | 15 (0.4) | 11 (0.6) | 4 (0.2) | 4 (0.1) | 1 (0.1) | 3 (0.2) | 30 (1.9) | |
| Asian | 337 (8.1) | 163 (8.5) | 174 (7.8) | 249 (8.1) | 103 (7.3) | 146 (8.9) | 131 (8.4) | |
| Black or African American | 429 (10.3) | 199 (10.4) | 230 (10.3) | 462 (15.1) | 226 (15.9) | 236 (14.4) | 158 (10.1) | |
| Multiple Races | 42 (1.0) | 15 (0.8) | 27 (1.2) | 115 (3.8) | 40 (2.8) | 75 (4.6) | 25 (1.6) | |
| Native Hawaiian or Other Pacific Islander | 21 (0.5) | 10 (0.5) | 11 (0.5) | 12 (0.4) | 3 (0.2) | 9 (0.5) | 9 (0.6) | |
| Unknown | 1268 (30.5) | 555 (28.9) | 713 (31.8) | 500 (16.4) | 287 (20.2) | 213 (13.0) | 591 (37.8) | |
| White or Caucasian | 2049 (49.2) | 967 (50.4) | 1082 (48.3) | 1715 (56.1) | 759 (53.5) | 956 (58.4) | 618 (39.6) | |
| Heart comorbidities, n (%) | ||||||||
| No | 1115 (26.8) | 516 (26.9) | 599 (26.7) | 584 (17.9) | 189 (12.9) | 395 (21.9) | 1074 (68.8) | |
| Yes | 3046 (73.2) | 1404 (73.1) | 1642 (73.3) | 2679 (82.1) | 1273 (87.1) | 1406 (78.1) | 488 (31.2) | |
| Liver comorbidities, n (%) | ||||||||
| No | 1159 (27.9) | 532 (27.7) | 627 (28.0) | 1353 (41.5) | 528 (36.1) | 825 (45.8) | 1220 (78.1) | |
| Yes | 3002 (72.1) | 1388 (72.3) | 1614 (72.0) | 1910 (58.5) | 934 (63.9) | 976 (54.2) | 342 (21.9) | |
| Infection comorbidities, n (%) | ||||||||
| No | 1709 (41.1) | 821 (42.8) | 888 (39.6) | 925 (28.3) | 291 (19.9) | 634 (35.2) | 1334 (85.4) | |
| Yes | 2452 (58.9) | 1099 (57.2) | 1353 (60.4) | 2338 (71.7) | 1171 (80.1) | 1167 (64.8) | 228 (14.6) | |
| Other comorbidities, n (%) | ||||||||
| No | 3925 (94.3) | 1831 (95.4) | 2094 (93.4) | 3142 (96.3) | 1423 (97.3) | 1719 (95.4) | 1315 (84.2) | |
| Yes | 236 (5.7) | 89 (4.6) | 147 (6.6) | 121 (3.7) | 39 (2.7) | 82 (4.6) | 247 (15.8) | |
Age data was missing from 36 patients in the UCLA: CRRT cohort. Age, sex, ethnicity, and race data was missing from 206 patients in the Cedars: CRRT cohort. Note that comorbidities were identified if the CCS codes described in Section “Data Preprocessing” were recorded within 14 days before starting CRRT, which reflected the optimal window of the comprehensive model.